The retina is the only part of the central nervous system visible without surgery. Its vasculature, neural tissue, and structural changes mirror — and often precede — pathology throughout the body. MicroFuseTech's deep learning models decode these signals with clinical-grade precision.
Our proprietary biomarker library, built from 4.2 million annotated fundus images across three continents, enables detection of conditions that would otherwise require invasive testing, costly imaging, or years of symptom progression. Crucially, our AI operates entirely on-device — no internet connection required.
Fully offline · No internet required · On-device AI
4.2M
Training Images
98.1%
Specificity
98.1%
Sensitivity
CE / FDA / UKCA, FCC, ISO
Regulatory Pathway
02Built for Every Setting
Designed to scale without limits
🏥
Hospitals
Seamlessly integrates into ward rounds, outpatient clinics, and specialist departments with EHR connectivity.
🏪
Clinics
Primary care and specialist clinics gain diagnostic power without expensive imaging suites or specialist referrals.
🔬
Diagnostic Centers
High-throughput screening programs with batch reporting, longitudinal tracking, and population analytics.
🚑
Emergency Units
Rapid triage support with instant AI results — no network dependency, no infrastructure barriers.
🚐
Mobile Care Units
Extend specialist diagnostics to remote, underserved communities. Battery-powered and fully offline-capable.
03Technology
How we decode the retina
Six pillars of innovation working in concert to deliver unprecedented diagnostic power from a device that fits in a coat pocket — with no internet required.
01
High-Fidelity Optical System
20-megapixel CMOS sensor with custom wide-field optics. 45° field of view, autofocus in under 3 seconds, no pupil dilation required. Any operator, any environment.
02
Cipher AI Engine
Our proprietary vision transformer — Cipher — analyzes 847 distinct retinal biomarkers simultaneously. Trained on the world's largest annotated retinal imaging dataset with continuous learning.
03
Predictive Risk Modeling
Track biomarker progression over time. Our longitudinal models generate individualized disease probability curves — enabling proactive intervention and patient journey forecasting.
04
Offline-First Architecture
Complete on-device AI inference. No internet, no cloud dependency, no latency. Scans, analyzes, and delivers results in under 60 seconds in any location on earth.
05
EHR & System Integration
HL7 FHIR, Epic, Cerner, and custom API connectivity. When online, results sync automatically to clinical records. HIPAA-compliant. GDPR-ready.
06
Explainable AI Reporting
Every result includes visual saliency maps, confidence intervals, and peer-literature references — giving clinicians transparent, trustworthy diagnostic intelligence they can act on.
04The Device
Clinical imaging. Anywhere.
The MFT-1 Pro is a handheld fundus camera purpose-built for AI-powered systemic disease screening. Designed for primary care, population health, and remote settings where traditional diagnostic infrastructure doesn't exist — and built to operate completely offline.
Sensor
12MP CMOS, >60lp/mm, Autofocus, White LED and IR LED
Field of View
50° (up to 80°)
Format
JPEG, MPEG-4/1, Dicom3.0, JSON, txt, FHIR, EHRxF
Battery
3.7V/3500mAh / 200+ captures
Mydriasis
Not required, less than 2.5mm Pupil
Connectivity
USB3.0, WIFI, SD card, HDMI, BT 5.2
Offline AI
100% on-device
Scan Time
5s bilateral
Certifications
CE Mark, FDA 510(k), UKCA, FCC, ISO
Display
4.7″ TFT colored IPS touchscreen
05Indications
One scan. Fifteen+ conditions.
Alzheimer's
Cardiovascular
Diabetic Retinopathy
Malaria
Cancer
Hypertension
Parkinson's
Macular Degen.
Alzheimer's Disease
Amyloid-beta plaques deposit in the retina years before cortical accumulation reaches detectable levels. MicroFuseTech identifies characteristic vascular attenuation patterns, RNFL thinning, and amyloid fluorescence signatures predictive of neurodegenerative trajectory.
The retinal microvasculature directly mirrors coronary and cerebrovascular circulation. Arteriovenous nicking, copper-wiring, vessel caliber asymmetry, and microaneurysms correlate strongly with hypertension severity, stroke risk, and atherosclerotic burden.
Arteriovenous nicking and crossing changes
Central retinal artery/vein diameter ratios
Arterial wall reflex (copper/silver wiring)
Microaneurysm density mapping
Vascular tortuosity indices
Diabetic Retinopathy
From subclinical microaneurysms to proliferative neovascularization, MicroFuseTech grades diabetic retinopathy across the full ETDRS severity spectrum. Early identification of macular edema risk prevents vision loss and guides treatment timing.
Microaneurysm count and distribution
Hard exudate proximity to fovea
Intraretinal microvascular abnormalities
Neovascularization elsewhere/disc
Macular edema risk stratification
Malaria Retinopathy
Malaria retinopathy is a powerful predictor of cerebral malaria severity and mortality in endemic regions. MicroFuseTech detects characteristic whitening patterns, vessel changes, and hemorrhages that stratify risk and guide urgent intervention — with full offline capability for remote settings.
Paraneoplastic retinopathy caused by autoimmune responses to systemic malignancies produces characteristic visual field loss, photoreceptor dysfunction, and vascular changes. Our AI identifies these signatures as early systemic cancer indicators before primary tumor diagnosis.
Photoreceptor layer attenuation patterns
Retinal arteriolar attenuation
Electroretinogram-correlated structural changes
Outer nuclear layer thinning
Anti-recoverin antibody-associated changes
Hypertension Retinopathy
Chronic hypertension produces progressive retinal vascular changes that MicroFuseTech grades from Grade I through Grade IV. Early-stage detection — before end-organ damage — enables timely antihypertensive intervention and cardiovascular risk reduction.
Arteriolar narrowing and irregularity
Arteriovenous nipping at crossings
Flame-shaped hemorrhages
Cotton wool spots (nerve fiber infarcts)
Disc edema in malignant hypertension
Parkinson's Disease
Alpha-synuclein deposition and dopaminergic neurodegeneration leave measurable signatures in retinal structure and function. Inner plexiform layer thinning and characteristic retinal dopamine system changes precede motor symptom onset by 5–10 years.
Inner plexiform layer (IPL) thickness reduction
Dopaminergic amacrine cell loss patterns
Foveal pit morphology changes
Retinal alpha-synuclein deposition
Saccadic eye movement analysis
Macular Degeneration
Age-related macular degeneration is the leading cause of vision loss in adults over 60. MicroFuseTech detects and characterizes drusen burden, geographic atrophy extent, and choroidal neovascularization — enabling early anti-VEGF therapy to preserve vision.
Drusen size, volume, and distribution mapping
Geographic atrophy area quantification
Choroidal neovascularization (CNV) detection
Pigmentary changes and RPE disruption
AMD severity grading (AREDS classification)
Patient Risk Trajectory — 7-Year Projection
The Platform
Predict the
patient's journey
MicroFuseTech's predictive platform empowers clinicians to look beyond diagnosis — into the trajectory of disease. Using longitudinal retinal biomarker data, our models forecast how a patient's condition will evolve, enabling precision intervention timing.
📈
Recovery Journey Forecasting
Model the expected recovery curve post-intervention and identify patients likely to respond to specific treatment protocols.
📉
Degenerative Trajectory Mapping
Visualize the rate and pattern of disease progression to plan proactive care milestones and specialist referral windows.
🧬
Disease Predisposition Prediction
Identify patients at elevated risk of developing conditions years before onset — enabling preventive lifestyle and pharmacological interventions.
The future of preventive health
begins here
Join leading health systems, research institutions, and population health programs deploying MicroFuseTech in clinical practice — from urban hospitals to the world's most remote communities.
Trusted by
Grand Challenges CanadaJohnson & Johnson InnovationWHO AfroIHK BerlinSavvyHealthcareASME
MicroFuseTech · Schedule
Request a Demo
Experience the MFT-1 Pro and Cipher AI platform firsthand. Our clinical team will guide you through a full demonstration tailored to your setting.
✅
Request Received
Thank you! Our clinical team will contact you within 24 hours to confirm your demonstration.
MicroFuseTech · Partnerships
Partner with Us
Join our global network of clinical, research, and commercial partners advancing retinal biomarker diagnostics worldwide.
✅
Partnership Request Sent
Thank you for your interest. Our partnerships team will be in touch within 2 business days.
Our Story
About MicroFuseTech
MicroFuseTech was founded on a singular conviction: that the eye holds the map to the body's health, and that every person on earth deserves access to the intelligence it contains. We are a biotech company at the intersection of precision optics, on-device AI, and clinical medicine.
Our Mission
To democratize early disease detection by putting the world's most advanced retinal biomarker platform into the hands of every clinician — from a specialist in a Boston hospital to a community health worker in rural Nigeria — without requiring a single bar of connectivity.
The Problem We Solve
Millions of deaths each year are attributable to diseases that were detectable years before they became fatal — but weren't, because the diagnostic tools required cost hundreds of thousands of dollars, require specialist operators, and exist only in resource-rich environments. MicroFuseTech changes this equation entirely.
What Makes Us Different
The only handheld fundus AI platform with 100% offline diagnostic capability
15+ systemic disease indications from a single 40-second scan
Predictive platform for patient recovery and degenerative trajectory modeling
Built for scale across hospitals, mobile units, and community settings
Trained on 4.2 million annotated retinal images from 3 continents
Our Team
Our multidisciplinary team brings together world-leading ophthalmologists, machine learning researchers, embedded systems engineers, and global health experts united by a shared belief: that preventive care is the most powerful medicine we have, and that retinal intelligence is its next frontier.
Platform · Technology
Cipher
The world's most advanced retinal biomarker decoding engine.
Cipher is MicroFuseTech's proprietary deep learning framework — purpose-built for retinal biomarker analysis. It is not an adaptation of a general vision model; it was designed from the ground up for the unique optical and biological characteristics of the fundus image.
Architecture
Vision Transformer (ViT) backbone with retina-specific attention heads
Multi-scale feature extraction across all retinal layers
847 simultaneously analyzed biomarker signatures
Disease-specific submodels with ensemble voting for diagnostic confidence
Quantized model weights optimized for on-device inference (sub-2W power)
Training & Validation
4.2 million annotated fundus images across 15+ disease indications
Validated against grading by sub-specialist ophthalmologists
Prospective clinical validation studies across 12 health systems
Continuous federated learning from deployed units (when online)
On-Device Deployment
Cipher runs entirely on the MFT-1 Pro's integrated AI processor — no cloud required, no network latency. Full inference completes in under 8 seconds, delivering a complete multi-disease diagnostic report alongside visual saliency maps and confidence scores.
The MicroFuseTech AI Engine is the complete software stack that powers retinal biomarker analysis — from raw image capture through to clinical report generation. It encompasses Cipher (the core model), the inference runtime, reporting engine, and longitudinal analytics layer.
Key Capabilities
Multi-disease simultaneous analysis from a single fundus image
Real-time image quality assessment and capture guidance
Explainable AI: every finding backed by a visual saliency heatmap
Structured clinical reports in PDF and HL7 FHIR format
Longitudinal trend analysis across serial patient scans
Offline & Privacy-First
Zero data transmitted for diagnostic inference — ever
Patient data encrypted at rest on-device (AES-256)
HIPAA compliant, GDPR ready by design
Optional cloud sync when connectivity is available
Performance Benchmarks
94.7% sensitivity across validated disease indications
98.1% specificity (vs. subspecialist graders)
Complete inference in under 8 seconds on-device
Full report generation in under 60 seconds from scan to output
Platform · Analytics
Predictive Platform
Empower clinicians to forecast patient outcomes — before they happen.
The MicroFuseTech Predictive Platform transforms serial retinal scans into a longitudinal intelligence layer — giving clinicians the ability to see not just where a patient is today, but where they are headed, and when to intervene.
Recovery Journey Forecasting
Model expected recovery curves following pharmacological or surgical intervention
Identify early and late responders to anti-VEGF, antihypertensive, and anti-diabetic therapies
Visualize rate and pattern of progressive disease across key retinal biomarkers
Automated milestone alerts when trajectory crosses intervention thresholds
Comparative benchmarking against age and demographic-matched cohorts
Disease Predisposition Prediction
Screen apparently healthy patients for elevated biomarker risk signatures
Stratify population cohorts by 5-year disease development probability
Generate actionable preventive care recommendations for at-risk individuals
Clinical Integration
The Predictive Platform is available as a web dashboard, tablet application, and API. It integrates with leading EHR systems and supports both individual clinician and population health workflows.
Request Platform Access
✅
Access Request Sent
Our team will be in touch within 2 business days with access credentials and onboarding information.
Platform · Integration
EHR Integration
Seamless connection to your existing clinical workflow.
MicroFuseTech integrates natively with leading electronic health record systems, allowing retinal diagnostic reports to flow directly into patient records without manual data entry or workflow disruption.
Supported Systems
Epic (SMART on FHIR App Gallery certified)
Cerner / Oracle Health
Meditech Expanse
Allscripts / Veradigm
Any HL7 FHIR R4 compliant system
Custom integration via REST API
Integration Features
Automatic patient matching via MRN / NHS number / national ID
Structured diagnostic results in FHIR DiagnosticReport format
Retinal images stored as FHIR DocumentReference (DICOM-compatible)
Clinician worklist integration and result notification
Bi-directional order and result messaging (HL7 v2 ADT/ORU)
Security & Compliance
HIPAA Business Associate Agreement (BAA) included
GDPR Article 28 compliant data processing
TLS 1.3 in-transit encryption, AES-256 at-rest
Role-based access control and full audit logging
✅
Integration Request Submitted
Our integration team will contact you within 3 business days to begin your EHR onboarding.
Platform · Developers
API Access
Embed retinal biomarker intelligence into your own applications.
The MicroFuseTech API gives developers and healthcare technology companies direct programmatic access to our Cipher AI engine — enabling retinal biomarker analysis to be embedded into any clinical application, telehealth platform, or research tool.
API Capabilities
Submit fundus images via REST API and receive structured diagnostic JSON
Access to all 15+ disease indication models
Retrieve visual saliency heatmaps and confidence scores
Longitudinal patient tracking and series management endpoints
Webhook support for asynchronous result delivery
Technical Specifications
RESTful API with OpenAPI 3.0 specification
SDKs available for Python, JavaScript, Swift, and Kotlin
DICOM and JPEG/PNG image input support
Response time: under 3 seconds for cloud inference
99.95% uptime SLA with global CDN delivery
Pricing & Access Tiers
Research Tier: 500 scans/month — free for accredited institutions
Startup Tier: 5,000 scans/month — contact for pricing
Enterprise: unlimited volume with dedicated infrastructure
✅
API Request Received
Our developer relations team will send your API credentials and documentation within 24 hours.
